pharma · Patency of the Ductus Arteriosus · Atopic Dermatitis · CNTB
S.L
S.L is a pharma organization headquartered in SAN DIEGO, CA, EU. It trades on NYSE under ticker CNTB. Primary therapeutic focus areas include Patency of the Ductus Arteriosus, Atopic Dermatitis, Chronic Rhinosinusitis Wi
SAN DIEGO, CA, EU HQ
Public company Type
CNTB · NYSE Ticker
Company details
- Status
- Public
- HQ
- SAN DIEGO, CA, EU
- Programs
- 15
- Drugs
- 11
- Patents
- 179
Double-Blind 0.2mg CBP-307
Phase 2 · small molecule · Moderate to Severe Ulcerative Colitis
Double-Blind 0.2mg CBP-307 for Moderate to Severe Ulcerative Colitis is a Phase 2 program (small_molecule) at S.L with 1 ClinicalTrials.gov record(s).
Internal code CBP-307CN002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- S.L
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Moderate to Severe Ulcerative Colitis
- Status
- completed
- Trials
- 1